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Heidi Y. Yu,c Alysha G. Elliott,d Mark S. Butler,d Johnny X. Huang,d Matthew A. Cooperd
and Frederick M. Pfeﬀer*a
A small series of norbornane bisether diguanidines have been synthesized and evaluated as antibacterial
agents. The key transformation—bisalkylation of norbornane diol 6—was not successful using Williamson
methodology but has been accomplished using Ag2O mediated alkylation. Further functionalization to
incorporate two guanidinium groups gave rise to a series of structurally rigid cationic amphiphiles;
several of which (16d, 16g and 16h) exhibited antibiotic activity. For example, compound 16d was active
against a broad range of bacteria including Pseudomonas aeruginosa (MIC ¼ 8 mg mL1), Escherichia coli
(MIC ¼ 8 mg mL1) and methicillin-resistant Staphylococcus aureus (MIC ¼ 8 mg mL1).Introduction
Antibacterial resistance is now a global medical concern.1–4 A
decline in the number of pharmaceutical companies pursuing
new therapeutics, and the continued misuse of antibiotics has
only served to exacerbate the problem.1–5 Many antibacterial
agents that target the lipopolysaccharide (LPS) layer of Gram-
negative bacteria either possess or adopt an amphiphilic struc-
ture.6–10 It has also been shown that appropriate functionalization
of a rigidied core (such as a calixarene) enables facially
amphiphilic compounds to be constructed.7–11 The bicyclo[2.2.1]-
heptane (norbornane) scaﬀold represents one of the most
accessible, preorganized frameworks available and has a history
of use in many elds of chemistry. Biologically active examples
include: naxifylline 1 (an A1-adenosine receptor antagonist),12 N
6-
(5,6-epoxynorbornyl)adenonsines (A1-adenosine receptor
agonists)13–15 and diguanidine 3, (active against Gram-negative
bacteria).16 In supramolecular chemistry norbornanes have
found use in organogel formation,17 whilst fused poly-
norbornanes have been successfully employed as scaﬀolds fornology, School of Life and Environmental
, Victoria, 3216, Australia. E-mail: fred.
ersity of Melbourne, Parkville, Victoria,
s, Monash Institute of Pharmaceutical
052, Australia
University of Queensland, Brisbane,
(ESI) available: Crystal structure of
edures for all previously reported
(1H, 13C, 19F) for all new compounds.
aphic data in CIF or other electronic
96both anion recognition,18–21 and as ligands for the construction of
metal–organic cages.22 In the eld of asymmetric synthesis, chiral
auxiliaries (such as 2) based on the norbornane framework have
also been successfully employed.23,24
It is known that ethers typically demonstrate better in vivo
stability than acetals,25 therefore, analogs of antibacterial 316
(Fig. 1) that followed the general structure 4 (Scheme 1) were
considered attractive targets. In order to construct this class of
compounds it was envisaged that bisether diacids (5) would be
useful building blocks and these could in turn be synthesized
from norbornane diol 6 (Scheme 1).
The direct alkylation of norbornane diol 6 is as yet unreported
in the literature, which is presumably because the reaction is
troublesome. Indeed, it has been shown that in some cases
alkylation of alcohols using typical Williamson protocols gives
lower than expected yields, or no desired product.26,27 Indeed, in
circumstances where a stabilized leaving group can be formed the
basic conditions employed can lead to an elimination/fragmen-
tation event.28,29 An example of this competitive elimination was
described by Hergueta et al. (Scheme 2); alkoxide 7, derived from a
norbornane fused to a quinoxaline, undergoes elimination to give
a carbanion (8) which is stabilized by the aromatic heterocyclic.30Fig. 1 Examples of functionalized norbornanes.
This journal is © The Royal Society of Chemistry 2015
Scheme 1 Access to bisether diguanidine 4 from diol 6.
Scheme 2 Ring opening to give stabilized ‘benzylic’ carbanion as
observed by Hergueta et al.30
Paper RSC Advances
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View Article OnlineThe use of silver(I) oxide for the transformation of an alcohol
to a methyl ether has been known for well over a century.31 The
Irvine–Purdie method has been used to achieve (i) mono-
alkylations;32–36 (ii) bisalkylation of unhindered diols such as
cycohexanediol;37 and (iii) per-methylation of carbohydrates
such as glucose, galactose and fructose.31,38 Ineﬃcient reaction
conditions (e.g. multiple additions of the alkylating agent34 or
carrying the reaction out in neat alkylating agent) means the
Irvine–Purdie alkylation is oen overlooked in favour of Wil-
liamson methodology. To the best of our knowledge, the use of
silver(I) oxide for the bisalkylation of eclipsed syn-1,2-diols has
not been previously described.
Herein, we report a protocol for the bisalkylation of the
sterically hindered 1,2-diol 6 using silver(I) oxide and a small
excess (4.6 equiv.) of suitable alkyl halides. Hydrolysis of the
esters gave access to compounds of the general structure 5,
which were shown to exist in a sterically congested environment
around the two alkyl groups by X-ray crystallography. Subse-
quent functionalization aﬀorded a series of diguanidines (4,
Scheme 1), that were tested against a range of Gram-negative
and Gram-positive bacteria (Tables 3 and 4).Scheme 3 Failed attempt to access bisether 9a and the possible
pathway leading to enolate 11.Results & discussion
Chemistry
The starting diester diol 6 was synthesized in two steps from
dimethyl fumarate.16,39 The norbornane framework was con-
structed using either standard Diels–Alder conditions (99%) orThis journal is © The Royal Society of Chemistry 2015by a solvent-free, microwave-assisted approach (2 hours at
150 C, 98%) similar to that reported by Nencka and
co-workers.39 The syn-1,2-diol 6 was synthesized in excellent
yields (94%) on multigram scales (up to 4 g), using OsO4 (0.1
mol%) mediated dihydroxylation of the norbornene using 4-
methylmorpholine N-oxide (NMO) as a co-oxidant.16,40 Dihy-
droxylation using KMnO4, as detailed by Donohoe,41 was also
successful, albeit in lower yield (58%) (see ESI† for full reaction
conditions).
Williamson methodology was initially trialled using 6, NaH,
MeI, at 55 C (Scheme 2) and aer 16 hours the diol had been
completely consumed (as determined by TLC analysis).
However, examination of the crude product using 1H NMR
spectroscopy showed no signs of the desired bisether 9a.
Instead, a complex mixture (inseparable by column chroma-
tography) was produced. Deprotonation with n-BuLi in THF at
78 to 0 C was also trialled but again the reaction was
unsuccessful. Given that similar norbornane diols undergo
base-induced ring opening to give stabilized anions (Scheme
2),30 we propose that following deprotonation, a Grob-type
fragmentation occurs to give a stabilized enolate (11,
Scheme 3).42
The Sakai group have described the reduction of esters to the
corresponding ethers using Et3SiH in the presence of catalytic
InBr3.43 Unfortunately, in the current work, aer acetylation of
diol 6 to form diacetate 20 (63%, see Experimental section),41
reaction with InBr3 failed to produce the bisether product;
instead 1H NMR analysis indicated that a complex mixture of
products had formed.
In light of these failures, attention turned towards the use of
Ag2O.32–37,44,45 Indeed, when diol 6 was reacted with Ag2O (1.6
equiv.) and MeI (4.6 equiv.) in DMF at ambient temperature for
48 hours (Scheme 4), bisether 9a was isolated in good yield
(67%).33 Saponication of diester 9a gave the required bisether
diacid (12a) in 73% yield (Scheme 4). Extended reaction times,
adding further portions of MeI throughout the reaction, and
heating the reaction (both conventional and microwave irradi-
ation), did not lead to increased yields. Using Ag2CO3, AgNO3,
AgBF4 or AgPF6 gave none of the desired product with only
starting material recovered.RSC Adv., 2015, 5, 28582–28596 | 28583
Scheme 4 Synthesis of diacid 12a.
Table 1 Synthesis of bisether diacids 12a–i
Entry RX Diacid Yieldc (%)
1 MeI 12a 48
2 12b 37
3 12c 19
4 12d 51
5 12e 55
6 12f 25
7 12g 24
8 12h 28
9a 12i 25
10 N.Rb N.R
11 N.R N.R
12 N.R N.R
a Reaction was stirred for 4 days. b N.R ¼ no reaction. c Yield calculated
over two steps.
RSC Advances Paper
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View Article OnlineTo further test the scope of these reaction conditions a range
of benzyl halides were used. Using benzyl bromide (Table 1,
entry 2), bisether diacid 12b was attained over two steps (18%
using 300mg of 6). Pleasingly, when the reaction was performed
on a larger scale (900 mg of 6), the yield increased to 37%. A
Finkelstein approach46 using NaI did not increase the yield of
bisether diacid 12b. The low yields can be rationalized some-
what by the steric bulk introduced as a result of the rst ben-
zylation—the reaction with the second equivalent of benzyl
halide is considerably inhibited. Indeed, an appreciable
amount of the monoalkylated regioisomer (37%) was isolated
along with the desired bisether product 12b. Similarly, using 2-
methylbenzyl bromide, 12c was accessed in 19% yield (Table 1,
entry 3), and a reasonable quantity of a monoalkylated inter-
mediate was also isolated (39%). Despite the modest yields, this
protocol provided access to the desired norbornane bisethers—
a previously inaccessible family of compounds.
When a range of uorinated benzyl bromides were used
good yields of the desired bisether products were obtained.
Following the aforementioned two-step process, 12d (51%) and
12e (55%) were accessed using 4-(triuoromethyl)benzyl
bromide and 3-uorobenzyl bromide respectively (Table 1,
entries 4 and 5). Furthermore, when 4-uorobenzyl bromide
was employed to alkylate diol 6, and following hydrolysis of the
ester groups using NaOH/THF (Table 1, entry 6) diacid 12f was
obtained in moderate yield (25%) over the two steps.
Using 3-bromobenzyl bromide and 4-bromobenzyl bromide
the synthesis of bisether diacids 12g and 12h (24 and 28% over
two steps respectively, Table 1, entries 7 and 8) was carried out
in the same fashion. Crystals suitable for X-ray diﬀraction were
obtained for bisether diacid 12h aer recrystallization from
EtOH/pet. spirits. The resulting structure contained a unit cell
comprised of two conformational isomers (as shown in Fig. 2).
The O/O distance (ca. 2.6 A˚), clearly illustrates the proximity of
the two benzyl groups and their non-symmetric orientation
(presumably due to steric constraints).
When allyl bromide was used, stirring for 4 days was required
to consume all the startingmaterial; subsequent ester hydrolysis
gave diacid 12i in a 25% yield over the two steps (Table 1, entry
9). Unfortunately, reactions with 4-methoxybenzyl chloride and
4-nitrobenzyl bromide (Table 1, entries 10 and 11) failed to give
any of the desired product with only minimal consumption of
starting material taking place (as evidenced by 1H NMR analysis
of the crude reactionmixture). Also, when 1-iodooctane (Table 1,
entry 12) was employed alkylation was unsuccessful.28584 | RSC Adv., 2015, 5, 28582–28596In six of the alkylation reactions (12b, 12d–h) trans-
esterication occurred to a small extent (6–12%, as determined
using 1H NMR spectroscopy). This mixed-ester side-product
(example 13 from synthesis of 9b, Fig. 3) was diﬃcult to sepa-
rate from the desired dimethyl ester product using column
chromatography. The presumption that the more sterically
accessible exo methyl ester was replaced is based on a previous
report by Niwayama and co-workers that illustrated how the exo
face is less hindered than the endo face of related norbornane
diesters.40 Despite the presence of small amounts of mixed-esterThis journal is © The Royal Society of Chemistry 2015
Fig. 2 Thermal ellipsoid plot of the two independent molecular conﬁrmations (ellipsoids at 20% probability level) of compound 12h.
Fig. 3 Representative structure of proposed mixed-ester 13 formed
during reaction with BnBr.
Paper RSC Advances
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View Article Onlineby-products, in each case hydrolysis proceeded smoothly and
pure diacids were isolated in every instance.
With bisethers diacids (12a–i) in hand, functionalization to
the required amphiphiles was pursued. Attachment of 2-[2,3-
bis(tert-butoxycarbonyl)guanidino]ethylamine (14)47,48 to the
norbornane scaﬀold was carried out using EDCI and HOBt in
either DMF or CHCl3 usingmicrowave irradiation at 50 C for 30
minutes to give compounds 15a–i in moderate to good yields
(26–72%, Table 2). Subsequent deprotection was accomplished
using HCl (generated in situ from AcCl in MeOH) to give the
desired guanidines as the guanidinium chloride salts (16a–i,
Table 2).
A balance of both hydrophobicity and hydrophilicity is
essential for the antibacterial activity of structural amphi-
philes.49 In light of this, the calculated log P (c log P) values (the
log of the octanol/water partition coeﬃcient) were determined
for bisether diguanidines (16a–i) using http://www.
molinspiration.com soware (Table 2) and these will be dis-
cussed in relation to activity in the following section.
Biological evaluation
The antibacterial activity of these compounds was evaluated
against a range of Gram-negative and Gram-positive bacteria,This journal is © The Royal Society of Chemistry 2015including members of the ESKAPE pathogens;1 rst using the
disk diﬀusion assay to identify active compounds then micro-
broth dilution assays to determine minimum inhibitory
concentrations (MICs).
Bis-methyl ether 16a and allyl ether 16i, did not show any
inhibition in disk diﬀusion studies at 50 mg per disk (Table 3).
For the bis-benzyl ether 16b, a noticeable zone of inhibition
(ZOI) was observed (11 mm) against Pseudomonas aeruginosa.
The inclusion of small substituents to the phenyl rings, such as
2-methyl (16c), 3-uoro (16e) and 4-uoro (16f), led to improved
activity as shown by ZOI's of 14–16 mm against P. aeruginosa
and Klebsiella pneumoniae (Table 3). Furthermore, appreciable
ZOI's (11–15 mm) were also observed against Gram-positive
methicillin-resistant Staphylococcus aureus (MRSA). When
larger substituents occupied the 4-position of the phenyl ring,
inhibition of vancomycin-resistant Enterococcus faecium (VRE)
was also seen in addition to the aforementioned strains. The 4-
(triuoromethyl)benzyl (16d) and 4-bromobenzyl (16h) analogs
showed ZOI of 18 and 16 mm respectively for VRE (Table 3). The
3-bromobenzyl derivative (16g) was active against all pathogens
assessed in this study, and was the sole compound to exhibit
activity against Acinetobacter baumannii (ZOI ¼ 15 mm).
Comparison of ZOI between 16g and 16h indicates that activity
against A. baumannii, K. pneumoniae and E. faecium can be
inuenced by subtle changes to substituent locations and may
have implications in the design of subsequent compounds.
Given the promising results in the disk diﬀusion screen the
substituted benzyl ethers were subjected to a micro-broth
dilution assay to quantify MICs (Table 4). When smaller
substituents; 2-methyl (16c), 3-uoro (16e) and 4-uoro (16f)
displaying no MIC # 32 mg mL1 against any bacterial strain
tested (Table 4). When larger substituents were included on the
benzyl rings such as 4-(triuoromethyl)benzyl (16d) MIC values
of 32 mg mL1 against A. baumannii, and 8 mg mL1 against each
of P. aeruginosa, Escherichia coli and MRSA (Table 4) wereRSC Adv., 2015, 5, 28582–28596 | 28585
Table 2 Formation of HCl salts 16a–i and associated c log P values
Diacid R Diamide (yield, %) Diguanidineb (yield, %) c log Pc
12a Me 15a (72) 16a (96) 4.80
12ba 15b (57) 16b (96) 2.04
12c 15c (54) 16c (24) 1.23
12d 15d (56) 16d (66) 0.24
12e 15e (26) 16e (99) 1.76
12fa 15f (45) 16f (77) 1.71
12ga 15g (53) 16g (97) 0.47
12h 15h (26) 16h (99) 0.42
12i 15i (63) 16i (31) 3.94
a Reaction was performed in CHCl3.
b Product was isolated as an HCl salt. c Calculated using http://www.molinspiration.com soware.
RSC Advances Paper
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View Article Onlineobserved. The 3-bromo benzyl-substituted analog (16g) showed
a reasonable MIC against both Gram-negative P. aeruginosa (32
mg mL1) and Gram-positive MRSA (16 mg mL1) bacterial
strains. Furthermore, an MIC of 32 mg mL1 was observed for
the 4-bromo benzyl-substituted analog (16h) against MRSATable 3 Zone of inhibition (ZOI) as measured (in mm) using disk diﬀusio
Compound
16a 16b 16c 16
A. baumannii ATCC 19606 NTb NT — —
P. aeruginosa ATCC 27853 — 11 16 15
K. pneumoniae ATCC13883 — — 14 16
S. aureus MRSA ATCC 43300 — — 15 17
E. faecium VRE ATCC 700221 — — — 18
a Measuredaer incubationofdisk (6mmdiameter, 50mgperdisk) at 37 Cf
28586 | RSC Adv., 2015, 5, 28582–28596(Table 4). A correlation between antibacterial activity and c log P
was apparent with compounds with higher c log P values (Table
2) showing stronger antibacterial activity.
Given the encouraging MIC values for compounds 16d and
16g against MRSA (Table 4), both compounds were evaluatedna
d 16e 16f 16g 16h 16i COLc
— — 15 — —
16 15 16d 15 — 19
14 14 15 8 — 20
11 11 17d 18 — —
— — 7 16 — —
or20hours. b NT¼not tested. c Testedat 10mgperdisk. d As seen inFig. 4.
This journal is © The Royal Society of Chemistry 2015
Fig. 4 Antibacterial activity of compound 16g (50 mg per disk) against
P. aeruginosa (LHS) and MRSA (RHS) using a disk diﬀusion assay.
Table 5 Cytotoxicity values (% of cell survival at 24 h)
Compound
16d 16g
ATCC CRL-1573 HEK293 43 90
ATCC HB-8065 HepG2 56 96
Paper RSC Advances
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View Article Onlineagainst seven additional Gram-positive bacterial strains
including such S. aureus bacterial isolates as multi-resistant
methicillin resistant (mMRSA), glycopeptide-intermediate
(GISA) and vancomycin-intermediate (VISA), as well as Strepto-
coccus pneumoniae and E. faecalis (Table 5). The 4-(tri-
uoromethyl)benzyl bisether (16d) was again the most active
compound; exhibiting antibacterial activity (MIC ¼ 8–16 mg
mL1) against all eight bacterial strains tested. Furthermore,
activity was observed by 3-bromobenzyl bisether (16g) against
all Gram-positive bacterial strains tested which was highlighted
by an MIC of 8 mg mL1 against S. pneumoniae (Table 4).
The cell viability (% survival) against human embryonic
kidney cells (HEK293) and hepatocellular carcinoma (HepG2)
was determined aer exposure to compounds 16d or 16g at 100
mM for 24 hours (Table 5). The 4-(triuoromethyl)benzyl
bisether (16d) exhibited moderate cytotoxicity with 43 and 56%
cell survival observed against HEK293 and HepG2 respectively
(Table 5). In the case of bis-3-bromobenzyl ether (16g) the cell
viability was determined to be 90% and 96% against HEK293
and HepG2 respectively (IC50 < 100 mM). The cytotoxicity prole
for these compounds is acceptable when compared to previ-
ously reported antibacterial agents.50Table 4 MIC values (mg mL1)
Compound
16c 16d 16
A. baumannii ATCC 19606 >32 32 >3
P. aeruginosa ATCC 27853 >32 8 >3
K. pneumoniae ATCC 700603 >32 >32 >3
E. coli ATCC 25922 >32 8 >3
S. aureus MRSA ATCC 43300 >32 8 >3
S. aureus mMRSA NTa 16 NT
S. aureus GISA, NRS 17 NT 8 NT
S. aureus VISA, NRS 1 NT 16 NT
S. aureus MRSA NT 16 NT
S. aureus NARSA VRS 10 NT 8 NT
S. pneumoniae MDR ATCC 700677 NT 8 NT
VanA E. faecalis NT 8 NT
a NT ¼ not tested due to lack of activity against the primary Gram-pos
vancomycin.
This journal is © The Royal Society of Chemistry 2015Conclusions
The previously inaccessible norbornane bisether diacids 12a–i,
were successfully prepared using Ag2O and a suitable alkyl or
benzyl halide as the key step. An X-ray crystal structure of
bisether diacid 12h highlighted the sterically crowded envi-
ronment of the ethers; which presumably hindered the second
etherication step and resulted in lower yields. Nevertheless,
the protocol presented here provides a viable alternative for the
alkylation of congested syn-diols or base-sensitive alcohols
where typical Williamson ether synthesis conditions fail.
Further functionalization of bisether diacids (12a–i) gave a
series of bisguanidines as hydrochloride salts (16a–i).
Several of the compounds (16d, 16g and 16h) displayed
antibacterial activity, with MIC values as low as 8 mg mL1,
against a range of problematic bacterial species including P.
aeruginosa, E. coli, S. pneumonia, E. faecalis and several strains of
S. aureus. The results presented here reinforce the notion that
the activity of cationic antimicrobial peptides can be mimicked
by relatively small, structurally rigid amphiphiles. Indeed, when
compared to other synthetic scaﬀolds (such as calixarenes)
which are used to generate antibacterial amphiphiles,9 the low
molecular weight of these compounds and their reasonable
antibacterial activity make them an attractive class of
compounds worthy of further investigation.
Experimental section
The following compounds were prepared using literature methods
and full reaction details can be found in the ESI;† dimethyl bicyclo-
[2.2.1]hept-5-ene-3-endo-2-exo-dicarboxylate (17),39,51 616,41 and 14.47e 16f 16g 16h COLb VANc
2 >32 >32 >32 0.06 NT
2 >32 32 >32 0.25 NT
2 >32 >32 >32 0.03 NT
2 >32 >32 >32 0.06 NT
2 >32 16 32 NT 1
NT 32 NT NT 1
NT 16 NT NT 4
NT 32 NT NT 8
NT 32 NT NT 2
NT 16 NT NT 2
NT 8 NT NT 2
NT 32 NT NT >32
itive strain (MRSA ATCC 43300). b COL ¼ colistin sulphate. c VAN ¼
RSC Adv., 2015, 5, 28582–28596 | 28587
RSC Advances Paper
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View Article OnlineGeneral information
All microwave reactions were conducted using a CEM Discover
S-Class Explorer 48 Microwave Reactor, operating on a
frequency of 50/60 Hz and continuous irradiation power from
0–300 W. All reactions were performed in sealed reaction
vessels. All melting points are uncorrected. All 1H, 13C and 19F
NMR spectra were collected on either a 270 MHz FT-NMR
spectrometer, a 400 MHz FT-NMR spectrometer, or a 500 MHz
FT-NMR spectrometer where indicated. All 2D NMR experi-
ments were performed on a 500 MHz FT-NMR spectrometer.
Variable temperature (VT) NMR experiments were performed on
a 270 MHz FT-NMR spectrometer. Samples were dissolved in
CDCl3, DMSO-d6 or CD3OD where specied with the residual
solvent peak used as the internal reference – CDCl3; 7.26 (
1H)
and 77.0 (13C), DMSO-d6; 2.50 (
1H) and 39.52 (13C), CD3OD; 3.31
(1H) and 49.0 (13C).52 Proton spectra are reported as chemical
shi d (ppm) (integral, multiplicity (s ¼ singlet, br s ¼ broad
singlet, d¼ doublet, t¼ triplet, q ¼ quartet, quin¼ quintet and
m ¼ multiplet), coupling constant (Hz), assignment). Carbon
spectra are reported as chemical shi d (ppm) (integral, multi-
plicity (d ¼ doublet and q ¼ quartet), coupling constant (Hz))
were appropriate. Fluorine spectra are reported as chemical
shi d (ppm) and were externally referenced using 0.05% a,a,a-
triuorotoluene in CDCl3; 63.72 (19F).
High resolution mass spectral data was collected on using a
QTOF mass spectrometer (LC-1200 series) under the following
conditions: gas temperature (300 C), nitrogen drying gas
(10.0 Lmin1), capillary voltage (3500 V), fragmentor (140 V), and
nebuliser (45 psi) in a 80% MeCN in H2O solvent system.
Analyte solutions were prepared in HPLC grade methanol (conc.
1 mg mL1).
All chemicals and solvents were used as received without
further purication unless otherwise stated. Column chroma-
tography was performed on silica gel (230–400 mesh).
Dimethyl 5,6-diacetate bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxylate (20). The stirring solution of diol 6 (130 mg, 0.532
mmol), DMAP (13mg, 0.11 mmol), pyridine (171 mL, 2.13 mmol)
and CH2Cl2 (1.1 mL) was treated with AcCl (130 mL, 1.81 mmol)
slowly and the reaction was stirred at ambient temperature for
16 h. The resulting bright orange solution was quenched with
sat. NaHCO3 (6 mL) and extracted with CH2Cl2 (3 10 mL). The
combined organic phase was washed with 1 M HCl (10 mL),
dried (MgSO4), ltered and concentrated in vacuo to give a clear
oil that was puried by column chromatography (35–50% EtOAc
in pet. spirits). The title compound (110 mg, 63%) was isolated
as a clear oil; Rf¼ 0.68 (50% EtOAc in pet. spirits). 1H NMR (270
MHz, CDCl3) d 1.53 (1H, dt, J ¼ 11.0, 1.4 Hz, H7s), 1.94 (1H, dd,
J ¼ 11.0, 1.6 Hz, H7a), 2.01 (6H, s, 2  Me), 2.61 (1H, br s, H1),
2.64–2.66 (1H, m, H4), 2.87 (1H, dd, J ¼ 5.6, 1.2 Hz, H2), 3.23
(1H, app. t, J ¼ 5.6 Hz, H3), 3.69 (3H, s, Me), 3.73 (3H, s, Me),
4.75 (1H, dd, J ¼ 6.0, 1.6 Hz, H6), 4.87 (1H, dd, J ¼ 6.0, 1.4 Hz,
H5). 13C NMR (67.5 MHz, CDCl3) d 20.6, 20.7, 33.7, 44.6, 44.7,
46.1, 46.2, 52.4, 52.5, 72.4, 74.8, 169.7, 169.9, 172.2, 173.7.
HRMS (ESI, m/z) for C15H20O8 [M + H]
+ calc. 329.1231 found
329.1233.28588 | RSC Adv., 2015, 5, 28582–28596General procedure A for the bis-alkylation of diol 6
Anhydrous DMF (2.4 mL) was added to a pre-dried round-
bottom ask protected from light, containing diol 6 (3.7
mmol) and Ag2O (1.6 equiv.) at ambient temperature. To the
stirring solution was added the appropriate alkylating agent (4.6
equiv.) and the reaction was stirred for 48 h before the reaction
vessel was cooled to 4 C (refrigerator) for a further 16 h without
agitation. The resulting precipitate was removed by vacuum
ltration and washed with EtOAc (15 mL). The ltrate was
washed with H2O (3  10 mL), dried (MgSO4), ltered and
concentrated in vacuo to aﬀord the crude product which was
puried by column chromatography to give the desired
bisether.
Dimethyl 5,6-bis(methoxy) bicyclo[2.2.1]heptane-3-endo-2-
exo-dicarboxylate (9a). Compound 9a was prepared from diol 6
(915 mg, 3.74 mmol) and iodomethane (1.1 mL, 17.7 mmol)
according to general procedure A and was puried by column
chromatography (20% EtOAc in pet. spirits) to give the title
compound (682 mg, 67%) as a clear viscous oil; Rf ¼ 0.17 (20%
EtOAc in pet. spirits). 1H NMR (270 MHz, CDCl3) d 1.39 (1H,
dquin, J¼ 10.7, 1.6 Hz, H7s), 1.89 (1H, ddd, J¼ 10.7, 1.6, 1.5 Hz,
H7a), 2.64–2.69 (3H, m, H1, H2, H4), 3.20 (1H, dd, J ¼ 5.5, 0.8
Hz, H3), 3.29 (1H, dd, J ¼ 6.0, 1.7 Hz, H5), 3.37 (3H, s, Me), 3.42
(3H, s, Me), 3.46 (1H, dd, J ¼ 6.1, 1.8 Hz, H6), 3.70 (3H, s, Me),
3.72 (3H, s, Me). 13C NMR (67.5 MHz, CDCl3) d 32.9, 43.3, 44.8,
45.0, 46.4, 52.2, 52.4, 58.7, 58.8, 81.0, 84.1, 173.2, 174.2. HRMS
(ESI, m/z) for C13H20O6 [M + H]
+ calc. 273.1333; found 273.1328.
Dimethyl 5,6-bis(benzyloxy) bicyclo[2.2.1]heptane-3-endo-2-
exo-dicarboxylate (9b). Compound 9b was prepared from diol 6
(917 mg, 3.75 mmol) and benzyl bromide (2.1 mL, 17.3 mmol)
according to general procedure A and was puried by column
chromatography (10% EtOAc in pet. spirits) to give the title
compound (743 mg, 47%) as a clear oil; Rf¼ 0.43 (20% EtOAc in
pet. spirits). 1H NMR (500 MHz, CDCl3) d 1.45 (1H, dt, J ¼ 10.7,
1.5 Hz, H7s), 2.10 (1H, dd, J ¼ 10.7, 1.6 Hz, H7a), 2.64–2.65 (2H,
m, H1, H2), 2.70–2.71 (1H, m, H4), 3.19 (1H, app. t, J ¼ 5.3 Hz,
H3), 3.46 (1H, dd, J¼ 5.8, 1.6 Hz, H5), 3.60 (3H, s, Me), 3.62 (1H,
dd, J ¼ 5.9, 1.4 Hz, H6), 3.69 (3H, s, Me), 4.53–4.62 (4H, m, 2 
ArCH2), 7.25–7.38 (10H, m, ArH).
13C NMR (125 MHz, CDCl3) d
33.4, 44.2, 45.1, 45.9, 46.4, 52.2, 52.4, 72.5, 72.7, 77.9, 81.7, 127.7
(2  C), 127.9 (2  C), 128.0 (2  C), 128.4 (2 C), 128.5 (2 C),
138.4, 138.5, 173.1, 174.3. HRMS (ESI, m/z) for C25H28O6 [M +
Na]+ calc. 447.1778; found 447.1754.
Dimethyl 5,6-bis[(2-methylbenzyl)oxy] bicyclo[2.2.1]heptane-
3-endo-2-exo-dicarboxylate (9c). Compound 9c was prepared
from diol 6 (321 mg, 1.31 mmol) and 2-methylbenzyl bromide
(810 mL, 6.03 mmol) according to general procedure A and was
puried by column chromatography (10–20% EtOAc in pet.
spirits) to give the title compound (115 mg, 19%) as a clear oil;
Rf¼ 0.50 (20% EtOAc in pet. spirits). 1H NMR (500 MHz, CDCl3)
d 1.45 (1H, d, J ¼ 10.6 Hz, H7s), 2.10 (1H, dd, J ¼ 10.6, 1.4 Hz,
H7a), 2.27 (3H, s, ArMe), 2.30 (3H, s, ArMe), 2.67–2.68 (2H, m,
H1, H2), 2.70–2.71 (1H, m, H4), 3.19 (1H, app. t, J ¼ 5.3 Hz, H3),
3.49 (1H, dd, J ¼ 5.8, 1.4 Hz, H5), 3.62 (3H, s, Me), 3.64 (1H, dd,
J ¼ 5.7, 1.2 Hz, H6), 3.70 (3H, s, Me), 4.49–4.61 (4H, m, 2 
ArCH2), 7.10–7.20 (6H, m, ArH), 7.24–7.25 (1H, m, ArH), 7.31–This journal is © The Royal Society of Chemistry 2015
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View Article Online7.33 (1H, m, ArH). 13C NMR (125 MHz, CDCl3) d 18.9, 19.0, 33.4,
44.4, 45.1, 45.7, 46.5, 52.2, 52.4, 70.9, 71.0, 78.3, 82.0, 125.8,
125.9, 127.8 (2  C), 128.8, 128.9, 130.2, 130.3, 136.3, 136.4,
136.7, 136.9, 173.2, 174.3. HRMS (ESI, m/z) for C27H32O6 [M +
Na]+ calc. 475.2091; found 475.2073.
Dimethyl 5,6-bis[(4-triuoromethyl)benzyloxy] bicyclo[2.2.1]-
heptane-3-endo-2-exo-dicarboxylate (9d). Compound 9d was
prepared from diol 6 (315 mg, 1.29 mmol) and 4-(tri-
uoromethyl)benzyl bromide (910 mL, 5.93 mmol) according to
general A procedure and was puried by column chromatog-
raphy (10–20% EtOAc in pet. spirits) to give the title
compound (461 mg, 64%) as a clear oil; Rf ¼ 0.26 (20% EtOAc in
pet. spirits). 1H NMR (500 MHz, CDCl3) d 1.49 (1H, dt, J ¼ 10.7,
1.4 Hz, H7s), 2.10 (1H, dd, J ¼ 10.7, 1.6 Hz, H7a), 2.66–2.68 (2H,
m, H1, H2), 2.72–2.75 (1H, m, H4), 3.22 (1H, app. t, J ¼ 5.2 Hz,
H3), 3.52 (1H, dd, J ¼ 5.8, 1.6 Hz, H5), 3.63 (3H, s, Me), 3.67 (1H,
dd, J ¼ 5.8, 1.4 Hz, H6), 3.71 (3H, s, Me), 4.57–4.68 (4H, m, 2 
ArCH2), 7.38–7.42 (4H, m, ArH), 7.54–7.57 (4H,m, ArH).
13C NMR
(125 MHz, CDCl3) d 33.3, 44.2, 45.0, 45.8, 46.3, 52.3, 52.5, 71.8,
71.9, 78.6, 82.2, 124.2 (q, JCF¼ 270.6 Hz, 2 CF3), 125.3 (q, 3JCF¼
3.6 Hz, 2  CH), 125.4 (q, 3JCF ¼ 3.6 Hz, 2  CH), 127.7 (2  C),
127.8 (2  C), 129.9 (q, 2JCF ¼ 32.3 Hz), 130.0 (q, 2JCF ¼ 32.3 Hz),
142.4 (2 C), 173.1, 174.0. 19F NMR (470 MHz, CDCl3) d 63.02,
63.00. HRMS (ESI, m/z) for C27H26F6O6 [M + H]+ calc. 561.1706;
found 561.1718.
Dimethyl 5,6-bis[(3-uorobenzyl)oxy] bicyclo[2.2.1]heptane-
3-endo-2-exo-dicarboxylate (9e). Compound 9e was prepared
from diol 6 (333 mg, 1.36 mmol) and 3-uorobenzyl bromide
(770 mL, 6.26 mmol) according to general procedure A and was
puried by column chromatography (10–20% EtOAc in pet.
spirits) to give the title compound (326 mg, 52%) as a clear oil;
Rf¼ 0.31 (20% EtOAc in pet. spirits). 1H NMR (500 MHz, CDCl3)
d 1.47 (1H, dt, J ¼ 10.7, 1.5 Hz, H7s), 2.09 (1H, dd, J ¼ 10.7, 1.6
Hz, H7a), 2.65–2.67 (2H, m, H1, H2), 2.73 (1H, m, H4), 3.21 (1H,
app. t, J ¼ 5.3 Hz, H3), 3.47 (1H, dd, J ¼ 5.9, 1.6 Hz, H5), 3.62–
3.64 (4H, m, Me, H6), 3.70 (3H, s, Me), 4.52–4.62 (4H, m, 2 
ArCH2), 6.94–7.13 (6H, m, ArH), 7.25–7.30 (2H, m, ArH).
13C
NMR (125 MHz, CDCl3) d 33.3, 44.1, 45.0, 45.8, 46.3, 52.2, 52.5,
71.7, 71.9, 78.2, 81.9, 114.52 (d, 2JCF ¼ 21.6 Hz, 2  CH), 114.59
(d, 2JCF ¼ 21.1 Hz), 114.62 (d, 2JCF ¼ 21.6 Hz), 123.07 (d, 3JCF ¼
2.8 Hz), 123.23 (d, 3JCF ¼ 2.8 Hz), 129.94 (d, 4JCF ¼ 1.6 Hz),
130.00 (d, 4JCF¼ 1.7 Hz), 140.98 (d, 3JCF¼ 2.4 Hz), 141.04 (d, 3JCF
¼ 2.3 Hz), 163.00 (d, 1JCF¼ 244.6 Hz), 163.05 (d, JCF¼ 244.4 Hz),
173.1, 174.1. 19F NMR (470 MHz, CDCl3) d 113.77. HRMS (ESI,
m/z) for C25H26F2O6 [M + H]
+ calc. 461.1770; found 461.1784.
Dimethyl 5,6-bis[(4-uorobenzyl)oxy] bicyclo[2.2.1]heptane-
3-endo-2-exo-dicarboxylate (9f). Compound 9f was prepared
from diol 6 (308 mg, 1.26 mmol) and 4-uorobenzyl bromide
(720 mL, 5.80 mmol) according to general procedure A and was
puried by column chromatography (10–20% EtOAc in pet.
spirits) to give the title compound (157 mg, 27%) as a clear oil;
Rf¼ 0.30 (20% EtOAc in pet. spirits). 1H NMR (500 MHz, CDCl3)
d 1.45 (1H, dt, J ¼ 10.7, 1.5 Hz, H7s), 2.07 (1H, dd, J ¼ 10.7, 1.6
Hz, H7a), 2.64–2.65 (1H, m, H2), 2.66 (1H,m, H1), 2.69 (1H, dd, J
¼ 4.6, 1.4 Hz, H4), 3.20 (1H, app. t, J¼ 5.1 Hz, H3), 3.47 (1H, dd,
J¼ 5.8, 1.6 Hz, H5), 3.62 (1H, dd, J¼ 5.8, 1.5 Hz, H6), 3.64 (3H, s,
Me), 3.70 (3H, s, Me), 4.47–4.53 (2H, m, ArCH2), 4.54 (2H, m,This journal is © The Royal Society of Chemistry 2015ArCH2), 6.96–7.01 (4H, m, ArH), 7.23–7.30 (4H, m, ArH).
13C
NMR (125 MHz, CDCl3) d 33.3, 44.2, 45.1, 45.9, 46.3, 52.2, 52.4,
71.8, 72.0, 78.1, 81.8, 115.2 (d, 2JCF ¼ 21.2 Hz, 2  CH), 115.3 (d,
2JCF ¼ 21.1 Hz, 2  CH), 129.6 (d, 3JCF ¼ 9.2 Hz, 2  CH), 129.7
(d, 3JCF ¼ 8.4 Hz, 2  CH), 134.1 (d, 4JCF ¼ 3.4 Hz), 134.2 (d, 4JCF
¼ 2.9 Hz), 162.4 (d, 1JCF ¼ 244.0 Hz), 162.5 (d, 1JCF ¼ 244.3 Hz),
173.1, 174.1. 19F NMR (470 MHz, CDCl3) d 115.36, 115.30.
HRMS (ESI, m/z) for C25H26F2O6 [M + Na]
+ calc. 483.1590; found
483.1594.
Dimethyl 5,6-bis[(3-bromobenzyl)oxy] bicyclo[2.2.1]heptane-
3-endo-2-exo-dicarboxylate (9g). Compound 9g was prepared
from diol 6 (315 mg, 1.29 mmol) and 3-bromobenzyl bromide
(1.48 g, 5.93 mmol) according to general procedure A and was
puried by column chromatography (10–20% EtOAc in pet.
spirits) to give the title compound (266 mg, 35%) as a clear oil;
Rf¼ 0.27 (20% EtOAc in pet. spirits). 1H NMR (500 MHz, CDCl3)
d 1.47 (1H, dt, J ¼ 10.7, 1.4 Hz, H7s), 2.09 (1H, dd, J ¼ 10.7, 1.5
Hz, H7a), 2.66–2.67 (2H, m, H1, H2), 2.72 (1H, dd, J ¼ 4.6, 1.3
Hz, H4), 3.21 (1H, app. t, J ¼ 4.9 Hz, H3), 3.48 (1H, dd, J ¼ 6.0,
1.7 Hz, H5), 3.63 (1H, dd, J ¼ 5.7, 1.4 Hz, H6), 3.66 (3H, s, Me),
3.71 (3H, s, Me), 4.49–4.59 (4H, m, 2  ArCH2), 7.15–7.29 (4H,
m, ArH), 7.39–7.53 (4H, m, ArH). 13C NMR (125 MHz, CDCl3) d
33.3, 44.2, 45.1, 45.9, 46.3, 52.3, 52.5, 71.7, 71.9, 78.3, 82.0,
122.6, 122.7, 126.2, 126.3, 130.1 (2  C), 130.7, 130.8 (3  C),
140.7, 140.8, 173.1, 174.1. HRMS (ESI,m/z) for C25H26Br2O6 [M +
H]+ calc. 581.0169; found 581.0181.
Dimethyl 5,6-bis[(4-bromobenzyl)oxy] bicyclo[2.2.1]heptane-
3-endo-2-exo-dicarboxylate (9h). Compound 9h was prepared
from diol 6 (333 mg, 1.36 mmol) and 4-bromobenzyl bromide
(1.57 g, 6.26 mmol) according to general procedure A and was
puried by column chromatography (10–20% EtOAc in pet.
spirits) to give the title compound (279 mg, 35%) as a clear oil.
Rf¼ 0.36 (20% EtOAc in pet. spirits). 1H NMR (500 MHz, CDCl3)
d 1.45 (1H, d, J ¼ 10.7 Hz, H7s), 2.06 (1H, d, J ¼ 10.6 Hz, H7a),
2.64–2.65 (2H, m, H1, H2), 2.68–2.69 (1H, m, H4), 3.20 (1H, app.
t, J¼ 5.0 Hz, H3), 3.46 (1H, dd, J¼ 5.8, 1.6 Hz, H5), 3.61 (1H, dd,
J ¼ 5.8, 1.3 Hz, H6), 3.64 (3H, s, Me), 3.70 (3H, s, Me), 4.45–4.53
(4H, m, 2  ArCH2), 7.14–7.19 (4H, m, ArH), 7.42–7.45 (4H, m,
ArH). 13C NMR (125 MHz, CDCl3) d 33.3, 41.2, 45.1, 45.9, 46.3,
52.3, 52.5, 71.8, 72.0, 78.3, 81.9, 121.6 (2  C), 129.4 (2  C),
129.6 (2  C), 131.5 (2  C), 131.6 (2  C), 137.4, 137.5, 173.1,
174.1. HRMS (ESI, m/z) for C25H26Br2O6 [M + H]
+ calc. 581.0169;
found 581.0182.
Dimethyl 5,6-bis(allyloxy) bicyclo[2.2.1]heptane-3-endo-2-
exo-dicarboxylate (9i). Compound 9i was prepared from diol 6
(302 mg, 1.24 mmol) and allyl bromide (530 mL, 5.70 mmol)
according to general procedure A (but was stirred for 4 days) and
was puried by column chromatography (20% EtOAc in pet.
spirits) to give the title compound (107 mg, 29%) as a clear oil;
Rf¼ 0.44 (20% EtOAc in pet. spirits). 1H NMR (270 MHz, CDCl3)
d 1.41 (1H, dt, J ¼ 10.6, 1.5 Hz, H7s), 1.99 (1H, dd, J ¼ 10.7, 1.6
Hz, H7a), 2.58–2.59 (1H, m, H1), 2.64–2.68 (2H, m, H2, H4), 3.18
(1H, dd, J ¼ 5.3, 4.8 Hz, H3), 3.43 (1H, dd, J ¼ 5.9, 1.7 Hz, H5),
3.56 (1H, dd, J ¼ 5.9, 1.6 Hz, H6), 3.69 (3H, s, Me), 3.70 (3H, s,
Me), 4.01 (2H, dt, J¼ 5.6, 1.4 Hz, OCH2), 4.06 (2H, dt, J¼ 5.6, 1.4
Hz, OCH2), 5.13–5.31 (4H, m, 2  CH2CH), 5.81–5.98 (2H, m, 2
 CH2CH). 13C NMR (67.5 MHz, CDCl3) d 33.3, 44.2, 45.1, 46.0,RSC Adv., 2015, 5, 28582–28596 | 28589
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View Article Online46.4, 52.2, 52.4, 71.8, 71.9, 78.3, 81.8, 117.1 (2  C), 135.0 (2 
C), 173.2, 174.3. HRMS (ESI, m/z) for C17H24O6 [M + Na]
+ calc.
347.1465; found 347.1479.General procedure B for the hydrolysis of diesters 9a–i
A biphasic solution of the appropriate diester (0.71 mmol), 2 M
NaOH (1.5 mL) and THF (3.0 mL) was stirred at ambient
temperature for 16 h. All organic impurities were extracted with
CH2Cl2 (2  5 mL) and the remaining aqueous phase was
acidied using 4 M HCl (pH ¼ 1) and extracted with EtOAc (3 
10 mL). The combined organic phase was washed with brine (10
mL), dried (MgSO4), ltered and concentrated in vacuo to aﬀord
the required diacid.
5,6-Bis(methoxy) bicyclo[2.2.1]heptane-3-endo-2-exo-dicar-
boxylic acid (12a). The title compound 12a was prepared from
diester 9a (194 mg, 0.71 mmol) according to general procedure
B and isolated as a white waxy solid (127 mg, 73%). 1H NMR
(270 MHz, CDCl3) d 1.43 (1H, d, J ¼ 10.7 Hz, H7s), 1.96 (1H, d, J
¼ 10.0 Hz, H7a), 2.67–2.76 (3H, m, H1, H2, H4), 3.25 (1H, app. t,
J ¼ 5.4 Hz, H3), 3.41 (3H, s, Me), 3.44 (3H, s, Me), 3.45–3.50 (2H,
m, H5, H6). 13C NMR (67.5 MHz, CDCl3) d 33.1, 43.1, 44.8, 44.9,
46.3, 58.8, 58.9, 80.8, 84.1, 178.0, 179.2. HRMS (ESI, m/z) for
C11H16O6 [M + Cl]
 calc. 279.0641; found 279.0652.
5,6-Bis(benzyloxy) bicyclo[2.2.1]heptane-3-endo-2-exo-dicar-
boxylic acid (12b). The title compound 12b was prepared from
diester 9b (717 mg, 1.69 mmol) according to general procedure
B and isolated as a white powder (525 mg, 78%). 1H NMR (270
MHz, CDCl3) d 1.48 (1H, d, J ¼ 10.9 Hz, H7s), 2.17 (1H, d, J ¼
10.5 Hz, H7a), 2.63 (1H, d, J ¼ 5.6 Hz, H1), 2.73 (1H, br s, H2),
2.79 (1H, d, J¼ 4.0 Hz, H4), 3.23 (1H, app. t, J¼ 5.4 Hz, H3), 3.63
(2H, t, J ¼ 6.4 Hz, H5, H6), 4.57–4.67 (4H, m, 2  ArCH2), 7.23–
7.35 (10H, m, ArH). 13C NMR (67.5 MHz, DMSO-d6) d 32.9, 43.6,
44.7, 45.3, 46.1, 71.6, 71.7, 78.1, 81.5, 127.4 (2  C), 127.7 (4 
C), 128.1 (2 C), 128.1 (2 C), 138.5, 138.7, 173.6, 174.8. HRMS
(ESI, m/z) for C23H24O6 [M  H] calc. 395.1501; found
395.1504.
5,6-Bis(2-methylbenzyloxy) bicyclo[2.2.1]heptane-2-endo-2-
exo-dicarboxylic acid (12c). The title compound 12c was
prepared from diester 9c (121 mg, 0.27 mmol) according to
general procedure B and isolated as a clear oil (113 mg, 99%).
1H NMR (500 MHz, DMSO-d6) d 1.31 (1H, d, J ¼ 10.1 Hz, H7s),
1.85 (1H, d, J ¼ 9.4 Hz, H7a), 2.19 (3H, s, Me), 2.21 (3H, s, Me),
2.47 (1H, d, J ¼ 5.5 Hz, H4), 2.55 (1H, br s, H1), 2.61 (1H, d, J ¼
3.3 Hz, H2), 2.99 (1H, app. t, J ¼ 5.0 Hz, H3), 3.59 (1H, d, J ¼ 5.7
Hz, H5), 3.64 (1H, d, J ¼ 5.6 Hz, H6), 4.44–4.49 (2H, m, ArCH2),
4.53 (2H, br s, ArCH2), 7.08–7.18 (6H, m, ArH), 7.22–7.27 (2H, m,
ArH), 12.54 (2H, br s, 2  COOH). 13C NMR (125 MHz, DMSO-
d6) d 18.3 (2  C), 33.0, 43.6, 44.7, 45.2, 46.1, 70.0, 70.1, 78.5,
81.8, 125.5 (2  C), 127.5 (2  C), 128.3 (2  C), 129.8 (2  C),
136.1 (2  C), 136.5, 136.6, 173.6, 174.8. HRMS (ESI, m/z) for
C25H28O6 [M + Na]
+ calc. 447.1778; found 447.1787.
5,6-Bis[(4-triuoromethyl)benzyloxy] bicyclo[2.2.1]heptane-
3-endo-2-exo-dicarboxylic acid (12d). The title compound 12d
was prepared from diester 9d (423 mg, 0.755 mmol) according
to general procedure B and isolated as a white powder (316 mg,
79%); m.p: 114.8–143.7 C. 1H NMR (500 MHz, DMSO-d6) d 1.3428590 | RSC Adv., 2015, 5, 28582–28596(1H, d, J ¼ 10.1 Hz, H7s), 1.90 (1H, d, J ¼ 9.7 Hz, H7a), 2.48 (1H,
m, H2), 2.58 (1H, br s, H1), 2.62–2.63 (1H, m, H4), 3.01 (1H, dd, J
¼ 5.4, 4.8 Hz, H3), 3.62 (1H, d, J ¼ 5.6 Hz, H6), 3.72 (1H, d, J ¼
5.5 Hz, H5), 4.57–4.69 (4H, m, 2  ArCH2), 7.46–7.50 (4H, m,
ArH), 7.60–7.63 (4H, m, ArH), 12.58 (2H, br s, 2  COOH). 13C
NMR (125 MHz, DMSO-d6) d 33.0, 43.6, 44.6, 45.3, 46.0, 70.7,
70.8, 78.4, 81.7, 124.4 (q, 1JCF¼ 270 Hz, 2 CF3), 124.9 (q, 3JCF¼
3.3 Hz, 2  CH), 125.0 (q, 3JCF ¼ 3.3 Hz, 2  CH), 127.83 (2 C),
127.84 (q, 2JCF ¼ 31.6 Hz, 2  C), 127.9 (2  C), 143.5, 143.6,
173.6, 174.8. 19F NMR (470 MHz, DMSO-d6) d 61.43. HRMS
(ESI, m/z) for C25H22F6O6 [M + Na]
+ calc. 555.1213; found
555.1211.
5,6-Bis(3-uorobenzyloxy) bicyclo[2.2.1]heptane-3-endo-2-
exo-dicarboxylic acid (12e). The title compound 12e was
prepared from diester 9e (292 mg, 0.635 mmol) according to
general procedure B and isolated as a clear waxy solid (206 mg,
75%). 1H NMR (500 MHz, CD3OD) d 1.45 (1H, d, J ¼ 10.5 Hz,
H7s), 2.04 (1H, dd, J ¼ 10.5, 1.5 Hz, H7a), 2.61 (1H, dd, J ¼ 5.6,
0.9 Hz, H2), 2.65 (1H, br s, H1), 2.70 (1H, dd, J¼ 4.5, 1.4 Hz, H4),
3.16 (1H, dd, J¼ 5.5, 4.8 Hz, H3), 3.67–3.71 (2H, m, H5, H6), 4.56
(2H, s, ArCH2), 4.61 (2H, s, ArCH2), 6.96–7.00 (2H, m, ArH),
7.04–7.14 (4H, m, ArH), 7.27–7.33 (2H, m, ArH). 13C NMR (125
MHz, CD3OD) d 33.9, 45.2, 46.2, 47.2, 47.6, 73.7 (d,
4JCF ¼ 1.3
Hz), 72.8 (d, 4JCF ¼ 1.5 Hz), 80.0, 83.4, 115.2 (d, 2JCF ¼ 21.1 Hz),
115.3 (d, 2JCF ¼ 21.6 Hz), 115.4 (d, 2JCF ¼ 22.3 Hz), 115.5 (d, 2JCF
¼ 21.7 Hz), 124.4 (d, 3JCF ¼ 2.7 Hz), 124.5 (d, 3JCF ¼ 2.7 Hz),
130.98, 131.04, 142.6 (d, 3JCF ¼ 7.2 Hz), 142.7 (d, 3JCF ¼ 7.2 Hz),
164.26 (d, 1JCF ¼ 242.9 Hz), 164.28 (d, 1JCF ¼ 242.8 Hz), 175.7,
176.9. 19F NMR (470 MHz, CD3OD) d 116.06, 116.03. HRMS
(ESI, m/z) for C23H22F2O6 [M + Na]
+ calc. 455.1277; found
455.1264.
5,6-Bis(4-uorobenzyloxy) bicyclo[2.2.1]heptane-3-endo-2-
exo-dicarboxylic acid (12f). The title compound 12f was
prepared from diester 9f (115 mg, 0.25 mmol) according to
general procedure B and isolated as a white powder (103 mg,
94%); m.p: 198.1–199.5 C. 1H NMR (270 MHz, CDCl3) d 1.48
(1H, d, J¼ 10.6 Hz, H7s), 2.13 (1H, d, J¼ 10.8 Hz, H7a), 2.64 (1H,
d, J ¼ 5.8 Hz, H2), 2.72 (1H, br s, H1), 2.76–2.78 (1H, m, H4),
3.24 (1H, dd, J¼ 5.7, 4.8 Hz, H3), 3.56–3.64 (2H, m, H5, H6), 4.53
(2H, br s, ArCH2), 4.56 (2H, br s, ArCH2), 6.93–7.02 (4H, m, ArH),
7.23–7.31 (4H, m, ArH). 13C NMR (67.5 MHz, DMSO-d6) d 32.9,
43.6, 44.6, 45.3, 46.0, 70.8, 70.9, 78.0, 81.4, 114.8 (d, 2JCF ¼ 21.1
Hz, 2  CH), 114.9 (d, 2JCF ¼ 21.0 Hz, 2  CH), 129.6 (d, 3JCF ¼
8.0 Hz, 2 CH), 129.7 (d, 3JCF¼ 8.1 Hz, 2 CH), 134.7 (d, 4JCF¼
3.0 Hz), 134.9 (d, 4JCF ¼ 3.0 Hz), 161.5 (d, 1JCF ¼ 241.3 Hz, 2 
CF), 173.5, 174.7. 19F NMR (470 MHz, DMSO-d6) d 116.68.
HRMS (ESI, m/z) for C23H22F2O6 [M + Na]
+ calc. 455.1277; found
455.1270.
5,6-Bis(3-bromobenzyloxy) bicyclo[2.2.1]heptane-3-endo-2-
exo-dicarboxylic acid (12g). The title compound 12g was
prepared from diester 9g (265 mg, 0.455 mmol) according to
general procedure B and isolated as a white powder (171 mg,
68%); m.p: 76.0–78.1 C. 1H NMR (270 MHz, CDCl3) d 1.50 (1H,
d, J¼ 11.3 Hz, H7s), 2.16 (1H, d, J ¼ 11.1 Hz, H7a), 2.67 (1H, d, J
¼ 4.9 Hz, H2), 2.75 (1H, br s, H1), 2.79 (1H, d, J ¼ 4.3 Hz, H4),
3.27 (1H, app. t, J ¼ 5.6 Hz, H3), 3.62–3.67 (2H, m, H5, H6), 4.55
(2H, s, ArCH2), 4.58 (2H, s, ArCH2), 7.14–7.24 (4H, m, ArH), 7.36–This journal is © The Royal Society of Chemistry 2015
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View Article Online7.49 (4H, m, ArH). 13C NMR (67.5 MHz, CDCl3) d 33.5, 43.9, 44.9,
45.9, 46.2, 71.9, 72.0, 78.5, 81.9, 122.6, 122.7, 126.2, 126.4, 130.1,
130.2, 130.7, 130.8, 130.9 (2  C), 140.5, 140.6, 177.5, 178.6.
HRMS (ESI, m/z) for C23H22Br2O6 [M  H] calc. 550.9710;
found 550.9729.
5,6-Bis(4-bromobenzyloxy) bicyclo[2.2.1]heptane-3-endo-2-
exo-dicarboxylic acid (12h). The title compound 12h was
prepared from diester 9h (159 mg, 0.273 mmol) according to
general procedure B and isolated as a white powder (119 mg,
79%); m.p: 119.7–124.9 C. 1H NMR (500 MHz, CD3OD) d 1.43
(1H, d, J ¼ 10.4 Hz, H7s), 2.02 (1H, dd, J ¼ 10.4, 1.1 Hz, H7a),
2.60 (1H, d, J ¼ 5.4 Hz, H2), 2.63 (1H, br s, H1), 2.68 (1H, dd, J ¼
4.5, 1.3 Hz, H4), 3.15 (1H, app. t, J ¼ 5.4 Hz, H3), 3.65–3.68 (2H,
m, H5, H6), 4.50 (2H, m, ArCH2), 4.54–4.56 (2H, m, ArCH2),
7.19–7.24 (4H, m, ArH), 7.42–7.44 (4H, m, ArH). 13C NMR (125
MHz, CD3OD) d 33.9, 45.2, 46.2, 47.2, 47.6, 72.7, 72.8, 79.8, 83.3,
122.3, 122.4, 130.8 (2  C), 130.9 (2  C), 132.4 (4  C), 138.9,
139.1, 173.6, 174.8. HRMS (ESI, m/z) for C23H22Br2O6 [M  H]
calc. 550.9710; found 550.9723.
5,6-Bis(allyloxy) bicyclo[2.2.1]heptane-3-endo-2-exo-dicar-
boxylic acid (12i). The title compound 12i was prepared from
diester 9i (41 mg, 0.127 mmol) according to general procedure B
and isolated as a viscous yellow oil (127 mg, 73%). 1H NMR (270
MHz, CDCl3) d 1.41–1.45 (1H, m, H7s), 2.04 (1H, d, J ¼ 10.4 Hz,
H7a), 2.64–2.72 (3H, m, H1, H2, H4), 3.22 (1H, dd, J ¼ 5.5, 4.7
Hz, H3), 3.56–3.61 (2H, m, H5, H6), 4.03–4.10 (4H, m, 2 
OCH2), 5.12–5.32 (4H, m, 2  CH2CH), 5.82–5.99 (2H, m,
CH2CH).
13C NMR (125 MHz, CDCl3) d 33.2, 43.9, 44.9, 45.8,
46.2, 71.7, 71.8, 78.2, 81.6, 117.2, 117.3, 134.6, 134.7, 178.1,
179.2. HRMS (ESI, m/z) for C15H20O6 [M + Na]
+ calc. 319.1152;
found 319.1152.General procedure C for the amidation of diacids 12a–i
A microwave vial was charged with the appropriate carboxylic
acid, EDCI (3.0 equiv.), HOBt (0.1 equiv.) and dry DMF and was
stirred at ambient temperature for 30 min. Amino-
ethylguanidine 14 (3.0 equiv.) was then added and the reaction
was irradiated to 50 C for 30 min. The resulting homogenous
clear mixture was diluted with EtOAc (15 mL), washed with H2O
(3  8 mL), brine (8 mL), dried (MgSO4), ltered, and concen-
trated in vacuo to aﬀord a solid that was puried by column
chromatography (as specied below) to give the title compound.
3-endo-2-exo-Di[20-(200,300-di-tert-butoxycarbonylguanidino)-
ethylcarbamoyl]-5,6-bis(methoxy)bicyclo[2.2.1]heptane (15a).
Compound 15a was prepared from diacid 12a (96 mg, 0.39
mmol) and amine 14 (357 mg, 1.18 mmol) according to general
procedure C and aer purication by column chromatography
(EtOAc) was isolated as a clear oil (230 mg, 72%); Rf ¼ 0.25
(EtOAc). 1H NMR (500 MHz, CDCl3) d 1.45–1.47 (36H, m, 4  t-
Bu), 1.56 (1H, d, J¼ 10.2 Hz, H7a), 1.89 (1H, d, J¼ 10.2 Hz, H7s),
2.45 (1H, d, J ¼ 6.3 Hz, H2), 2.56 (1H, br s, H1), 2.68 (1H, br s,
H4), 2.82 (1H, app. t, J¼ 5.3 Hz, H3), 3.34 (3H, s, OMe), 3.36 (3H,
s, OMe), 3.38–3.60 (10H, m, 4 CH2, H5, H6), 6.69 (1H, t, J¼ 5.4
Hz, NH), 8.02 (1H, t, J¼ 3.4 Hz, NH), 8.45 (1H, t, J¼ 5.5 Hz, NH),
8.65 (1H, t, J¼ 5.6 Hz, NH), 11.44 (1H, s, NH), 11.48 (1H, s, NH).
13C NMR (125 MHz, CDCl3) d 28.1, 28.2, 28.3, 28.4, 33.8, 39.4,This journal is © The Royal Society of Chemistry 201539.8, 40.1, 40.3, 42.4, 42.9, 43.7, 45.0, 49.3, 58.4, 58.6, 79.5, 80.0,
81.1, 83.3, 83.8, 84.2, 153.1, 153.2, 156.8, 157.9, 163.0, 163.5,
172.3, 174.4. HRMS (ESI, m/z) for C37H64N8O12 [M + H]
+ calc.
813.4717; found 813.4733.
3-endo-2-exo-Di[20-(200,300-di-tert-butoxycarbonylguanidino)-
ethylcarbamoyl]-5,6-bis(2-methylbenzyloxy)bicyclo[2.2.1]heptane
(15c). Compound 15c was prepared from diacid 12c (62 mg, 0.15
mmol) and amine 14 (140 mg, 0.45 mmol) according to general
procedure C and aer purication by column chromatography
(50–70% EtOAc in pet. spirits) was isolated as a white solid (36
mg, 54%); Rf ¼ 0.71 (70% EtOAc in pet. spirits); m.p: 117.7–120.7
C. 1H NMR (500 MHz, CDCl3) d 1.46–1.48 (36H, m, 4  t-Bu),
1.63 (1H, d, J ¼ 10.2 Hz, H7s), 2.12 (1H, d, J ¼ 9.3, Hz, H7a), 2.25
(3H, s, ArMe), 2.27 (3H, s, ArMe), 2.48 (1H, d, J¼ 6.2 Hz, H2), 2.60
(1H, br s, H1), 2.73 (1H, d, J¼ 3.1 Hz, H4), 2.82 (1H, app. t, J¼ 4.7
Hz, H3), 3.23–3.55 (8H, m, 4 CH2), 3.58 (1H, d, J ¼ 5.5 Hz, H5),
3.61 (1H, d, J ¼ 5.8 Hz, H9), 4.50–4.58 (4H, m, 2  CH2Ar), 6.52
(1H, br s, NH), 7.08–7.19 (6H, m, ArH), 7.27–7.31 (2H, m, ArH),
8.00 (1H, t, J¼ 4.1 Hz, NH), 8.48 (1H, br s, NH), 8.67 (1H, t, J¼ 5.6
Hz, NH), 11.45 (1H, s, NH), 11.50 (1H, s, NH). 13C NMR (125MHz,
CDCl3) d 18.9, 19.0, 28.1, 28.2, 28.40, 28.42, 34.4, 39.2, 40.3, 40.5,
42.3, 44.1, 44.7, 45.2, 49.5, 70.8, 70.9, 78.7, 79.6, 80.2, 82.1, 83.4,
83.8, 125.7, 125.8, 127.6, 127.8, 128.7, 128.9, 130.1, 130.2, 136.6,
136.67, 136.69, 136.8, 153.19, 153.23, 156.7, 157.9, 172.3, 174.6.
HRMS (ESI, m/z) for C51H76N8O12 [M + H]
+ calc. 993.5655; found
993.5654.
3-endo-2-exo-Di[20-(200,300-di-tert-butoxycarbonylguanidino)-
ethylcarbamoyl]-5,6-bis[(4-triuoromethyl)benzyloxy]bicyclo-
[2.2.1]heptane (15d). Compound 15d was prepared from diacid
12d (151 mg, 0.28 mmol) and amine 14 (260 mg, 0.85 mmol)
according to general procedure C and aer purication by ash
column chromatography (EtOAc) was isolated as a clear oil (174
mg, 56%); Rf ¼ 0.45 (EtOAc). 1H NMR (500 MHz, CDCl3) d 1.44–
1.52 (36H, m, 4  t-Bu), 1.68 (1H, d, J ¼ 10.3 Hz, H7s), 2.13 (1H,
d, J ¼ 9.3 Hz, H7a), 2.48 (1H, d, J ¼ 6.0 Hz, H2), 2.65 (1H, br s,
H1), 2.79–2.80 (1H, m, H4), 2.85 (1H, dd, J ¼ 5.7, 4.5 Hz, H3),
3.23–3.56 (8H, m, 4  CH2), 3.58 (1H, d, J ¼ 6.1 Hz, H5), 3.62
(1H, dd, J ¼ 5.8, 1.2 Hz, H9), 4.55–4.67 (4H, m, 2  CH2Ar), 6.68
(1H, m, NH), 7.38–7.40 (4H, m, ArH), 7.51–7.54 (4H, m, ArH),
8.16 (1H, t, J¼ 4.0 Hz, NH), 8.49 (1H, m, NH), 8.72 (1H, t, J¼ 6.0
Hz, NH), 11.48 (1H, s, NH), 11.53 (1H, s, NH). 13C NMR (125
MHz, CDCl3) d 28.1, 28.2, 28.4, 34.3, 39.4, 40.1, 40.4, 42.5, 43.8,
44.6, 45.1, 49.4, 71.5, 71.6, 78.9, 79.7, 80.3, 82.1, 83.5, 84.0, 125.3
(q, 3JCF ¼ 3.5 Hz, 4  CH), 126.4 (q, 1JCF ¼ 270 Hz, 2  CF3),
127.66 (2 C), 127.72 (2 C), 129.7 (q, 2JCF¼ 32.6 Hz), 129.8 (q,
2JCF ¼ 32.6 Hz), 142.7, 142.8, 153.2 (2  C), 156.7, 158.1, 163.0,
163.4, 172.2, 174.3. 19F NMR (470 MHz, CDCl3) d 62.97. HRMS
(ESI, m/z) for C51H70F6N8O12 [M + H]
+ calc. 1101.5090; found
1101.5110.
3-endo-2-exo-Di[20-(200,300-di-tert-butoxycarbonylguanidino)-
ethylcarbamoyl]-5,6-bis(3-uorobenzyloxy)bicyclo[2.2.1]heptane
(15e). Compound 15e was prepared from diacid 12e (184 mg,
0.43 mmol) and amine 14 (290 mg, 1.28 mmol) according to
general procedure C and aer purication by column chroma-
tography (50–70% EtOAc in pet. spirits) was isolated as a white
solid (111 mg, 26%); Rf ¼ 0.58 (70% EtOAc in pet. spirits); m.p:
214.5–258.2 C (slow decomposition). 1HNMR (500MHz, CDCl3)RSC Adv., 2015, 5, 28582–28596 | 28591
RSC Advances Paper
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View Article Onlined 1.46–1.49 (36H, m, 4  t-Bu), 1.66 (1H, d, J ¼ 10.3 Hz, H7s),
2.12 (1H, d, J ¼ 9.3 Hz, H7a), 2.47 (1H, d, J ¼ 6.1 Hz, H1), 2.63
(1H, br s, H4), 2.78–2.79 (1H, m, H1), 2.84 (1H, app. t, J¼ 6.0 Hz,
H3), 3.25–3.60 (10H, m, 4 CH2, H5, H6), 4.51–4.61 (4H, m, 2 
CH2Ar), 6.62 (1H, br s, NH), 6.91–7.07 (6H, m, ArH), 7.22–7.28
(2H, m, ArH), 8.15 (1H, t, J ¼ 4.0 Hz, NH), 8.50 (1H, br s, NH),
8.72 (1H, br s, NH), 11.47 (1H, s, NH), 11.53 (1H, s, NH). 13C NMR
(125 MHz, CDCl3) d 28.1, 28.2, 28.4, 34.3, 39.3, 40.2, 40.6, 42.4,
43.7, 44.7, 45.1, 49.4, 71.5, 71.6, 78.5, 80.0, 80.4, 81.9, 83.6, 84.0,
114.3 (d, 2JCF¼ 21.4 Hz), 114.4 (d, 2JCF¼ 21.1 Hz), 114.5 (d, 2JCF¼
21.2 Hz), 114.6 (d, 2JCF ¼ 21.4 Hz), 123.07 (d, 3JCF ¼ 2.8 Hz),
123.16 (d, 3JCF ¼ 2.9 Hz), 129.8, 129.9, 141.3 (d, 3JCF ¼ 7.0 Hz),
141.4 (d, 3JCF¼ 7.1 Hz), 153.1, 153.2, 156.6, 158.0, 162.71, 162.73,
162.96 (d, 1JCF ¼ 244.0 Hz), 163.02 (d, 1JCF ¼ 244.0 Hz), 172.3,
174.5. 19F NMR (470 MHz, CDCl3) d 113.92, 113.86. HRMS
(ESI, m/z) for C49H70F2N8O12 [M + H]
+ calc. 1001.5154; found
1001.5165.
3-endo-2-exo-Di[20-(200,300-di-tert-butoxycarbonylguanidino)-
ethylcarbamoyl]-5,6-bis(4-bromobenzyloxy)bicyclo[2.2.1]heptane
(15h). Compound 15h was prepared from diacid 12h (171 mg,
0.31 mmol) and amine 14 (281 mg, 0.93 mmol) according to
general procedure C and aer purication by column chroma-
tography (50–70% EtOAc in pet. spirits) was isolated as a clear
oil (91 mg, 26%); Rf ¼ 0.48 (70% EtOAc in pet. spirits). 1H NMR
(500 MHz, CDCl3) d 1.46–1.48 (36H, m, 4 t-Bu), 1.64 (1H, d, J¼
10.3 Hz, H7s), 2.09 (1H, d, J ¼ 9.4 Hz, H7a), 2.46 (1H, d, J ¼ 6.1
Hz, H1), 2.60 (1H, br s, H4), 2.74 (1H, m, H2), 2.83 (1H, app. t, J
¼ 4.6 Hz, H3), 3.22–3.46 (4H, m, 2  CH2), 3.52–3.58 (6H, m, 2
 CH2, H5, H6), 4.46–4.55 (4H, m, 2  CH2Ar), 6.69 (1H, m,
NH), 7.14–7.17 (4H, m, ArH), 7.39–7.42 (4H, m, ArH), 8.09 (1H, t,
J ¼ 4.0 Hz, NH), 8.54 (1H, m, NH), 8.73 (1H, t, J ¼ 5.1 Hz, NH),
11.47 (1H, s, NH), 11.51 (1H, s, NH). 13C NMR (125 MHz, CDCl3)
d 28.1, 28.2, 28.4, 34.3, 39.3, 40.2, 40.5, 42.4, 43.8, 44.6, 45.1,
49.4, 71.56, 71.61, 78.6, 80.0, 80.4, 81.8, 83.6, 84.0, 121.4, 121.5,
129.5 (2  C), 129.6 (2  C), 131.4 (2  C), 131.5 (2  C), 137.6,
137.7, 153.1, 153.2, 156.7, 158.0, 162.8, 163.2, 172.2, 174.4.
HRMS (ESI, m/z) for C49H70Br2N8O12 [M + H]
+ calc. 1121.3553;
found 1121.3550.
3-endo-2-exo-Di[20-(200,300-di-tert-butoxycarbonylguanidino)-
ethylcarbamoyl]-5,6-bis(allyloxy)bicyclo[2.2.1]heptane (15i).
Compound 15i was prepared from diacid 12i (70 mg, 0.24
mmol) and amine 14 (214 mg, 0.71 mmol) according to general
procedure C and aer purication by column chromatography
(50–70% EtOAc in pet. spirits) was isolated as a clear oil (128
mg, 63%); Rf ¼ 0.34 (70% EtOAc in pet. spirits). 1H NMR (500
MHz, CDCl3) d 1.49–1.50 (36H, m, 4 t-Bu), 1.60 (1H, d, J¼ 10.3
Hz, H7s), 2.02 (1H, d, J ¼ 10.0 Hz, H7a), 2.48 (1H, d, J ¼ 6.2 Hz,
H4), 2.54 (1H, br s, H1), 2.66 (1H, d, J ¼ 2.9 Hz, H2), 2.82 (1H,
dd, J ¼ 6.0, 4.6 Hz, H3), 3.33–3.60 (10H, m, 4  CH2, H5, H6),
3.98–4.04 (4H, m, 2  OCH2), 5.10–5.14 (2H, m, CH2CH), 5.20–
5.27 (2H, m, CH2CH), 5.84–5.94 (2H, m, 2 CH2CH), 6.58 (1H, t,
J ¼ 5.1 Hz, NH), 8.03 (1H, t, J ¼ 3.9 Hz, NH), 8.48 (1H, br s, NH),
8.68 (1H, t, J¼ 5.8 Hz, NH), 11.46 (1H, s, NH), 11.50 (1H, s, NH).
13C NMR (125 MHz, CDCl3) d 28.17, 28.21, 28.41, 28.44, 34.2,
39.3, 40.2, 40.5, 42.5, 43.9, 44.9, 45.2, 49.4, 71.6, 71.7, 78.6, 80.2,
81.9, 83.4, 83.9 (2  C), 116.6, 116.9, 135.2, 135.3, 153.23,28592 | RSC Adv., 2015, 5, 28582–28596153.34, 156.7, 158.0, 172.4, 174.6. HRMS (ESI, m/z) for
C41H68N8O12 [M + H]
+ calc. 865.5030; found 865.5027.General procedure D for the amidation of diacids 12a–i
A microwave vial was charged with the appropriate carboxylic
acid, EDCI (3.0 equiv.), HOBt (0.1 equiv.) and dry CHCl3 and was
stirred at ambient temperature for 30 min. Amino-
ethylguanidine 14 (3.0 equiv.) was then added and the reaction
was irradiated to 50 C for 30 min. The resulting homogenous
clear mixture was diluted with CHCl3 (20 mL), washed with H2O
(2  10 mL), brine (8 mL), dried (MgSO4), ltered, and
concentrated in vacuo to aﬀord the crude material that was
puried by column chromatography (as specied below) to give
the title compound.
3-endo-2-exo-Di[20-(200,300-di-tert-butoxycarbonylguanidino)-
ethylcarbamoyl]-5,6-bis(benzyloxy)bicyclo[2.2.1]heptane (15b).
Compound 15b was prepared from diacid 12b (343 mg, 0.87
mmol) and amine 14 (786 mg, 2.60 mmol) according to general
procedure D and aer purication by column chromatography
(70% EtOAc in pet. spirits) was isolated as a clear oil (563 mg,
57%); Rf ¼ 0.43 (70% EtOAc in pet. spirits). 1H NMR (270 MHz,
CDCl3) d 1.45–1.49 (36H, m, 4  t-Bu), 1.63 (1H, d, J ¼ 10.8 Hz,
H7s), 2.12 (1H, d, J ¼ 10.4 Hz, H7a), 2.43 (1H, d, J ¼ 6.2 Hz, H2),
2.60 (1H, s, H1), 2.74–2.76 (1H, m, H4), 2.79–2.83 (1H, m, H3),
3.16–3.57 (10H, m, 4  CH2, H5, H6), 4.55 (2H, s, CH2Ar), 4.59
(2H, s, CH2Ar), 6.56 (1H, t, J ¼ 5.8 Hz, NH), 7.22–7.33 (10H, m,
ArH), 7.99 (1H, t, J ¼ 4.0 Hz, NH), 8.45 (1H, t, J ¼ 5.6 Hz, NH),
8.69 (1H, t, J¼ 4.0 Hz, NH), 11.45 (1H, s, NH), 11.53 (1H, s, NH).
13C NMR (67.5 MHz, CDCl3) d 28.1, 28.2, 28.4, 34.4, 39.2, 40.1,
40.4, 42.5, 43.8, 44.6, 45.1, 49.5, 72.2, 72.3, 78.3, 79.5, 80.1, 81.6,
83.3, 83.8, 127.5, 127.6, 127.8, 128.1, 128.3, 128.4, 138.6, 138.7,
153.2, 156.7, 158.0, 163.1, 163.6, 172.3, 174.5. HRMS (ESI, m/z)
for C49H72N8O12 [M + H]
+ calc. 965.5343; found 965.5371.
3-endo-2-exo-Di[20-(200,300-di-tert-butoxycarbonylguanidino)-
ethylcarbamoyl]-5,6-bis(4-uorobenzyloxy)bicyclo[2.2.1]heptane
(15f). Compound 15f was prepared from diacid 12f (86 mg, 0.20
mmol) and amine 14 (181 mg, 0.60 mmol) according to general
procedure D and aer purication by column chromatography
(50–70% EtOAc in pet. spirits) was isolated as a clear oil (90 mg,
45%); Rf ¼ 0.13 (50% EtOAc in pet. spirits). 1H NMR (270 MHz,
CDCl3) d 1.46–1.48 (36H, m, 4  t-Bu), 1.62–1.66 (1H, m, H7s),
2.12 (1H, d, J ¼ 10.7 Hz, H7a), 2.46 (1H, d, J ¼ 7.3 Hz, H2), 2.60
(1H, br s, H1), 2.72–2.75 (1H, m, H4), 2.83 (1H, app. t, J¼ 5.2 Hz,
H3), 3.28–3.60 (10H, m, 4 CH2, H5, H6), 4.48–4.53 (4H, m, 2 
CH2Ar), 6.58 (1H, t, J ¼ 5.3 Hz, NH), 6.92–7.00 (4H, m, ArH),
7.22–7.29 (4H, m, ArH), 8.07 (1H, t, J ¼ 4.1 Hz, NH), 8.47 (1H, t, J
¼ 5.7 Hz, NH), 8.70 (1H, t, J ¼ 5.9 Hz, NH), 11.48 (1H, s, NH),
11.52 (1H, s, NH). 13C NMR (67.5 MHz, CDCl3) d 28.1, 28.2, 28.4,
34.3, 39.4, 40.2, 40.4, 42.6, 43.8, 44.7, 45.2, 49.5, 71.6, 71.7, 78.6,
79.6, 80.2, 81.8, 83.4, 83.9, 115.0 (d, 2JCF ¼ 18.4 Hz, 2  CH),
115.3 (d, 2JCF ¼ 18.5 Hz, 2  CH), 129.5 (d, 3JCF ¼ 9.8 Hz, 2 
CH), 129.7 (d, 3JCF ¼ 9.9 Hz, 2  CH), 134.4 (d, 4JCF ¼ 3.2 Hz),
134.5 (d, 4JCF¼ 3.2 Hz), 162.3 (d, 1JCF¼ 243.7 Hz), 162.4 (d, 1JCF¼
243.7 Hz), 153.2 (2  C), 156.8, 158.1, 163.1, 163.6, 172.3, 174.4.
19F NMR (470 MHz, CDCl3) d115.17,115.10. HRMS (ESI,m/z)
for C49H70F2N8O12 [M + H]
+ calc. 1001.5154; found 1001.5157.This journal is © The Royal Society of Chemistry 2015
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View Article Online3-endo-2-exo-Di[20-(200,300-di-tert-butoxycarbonylguanidino)-
ethylcarbamoyl]-5,6-bis(3-bromobenzyloxy)bicyclo[2.2.1]heptane
(15g). Compound 15g was prepared from diacid 12g (170 mg,
0.31 mmol) and amine 14 (280 mg, 0.93 mmol) according to
general procedure D and aer purication by column chroma-
tography (70% EtOAc in pet. spirits) was isolated as a clear oil
(185 mg, 53%); Rf ¼ 0.32 (70% EtOAc in pet. spirits). 1H NMR
(500 MHz, CDCl3) d 1.46–1.49 (36H, m, 4 t-Bu), 1.66 (1H, d, J ¼
10.4 Hz, H7s), 2.12 (1H, dd, J¼ 10.4, 1.2 Hz, H7a), 2.47 (1H, d, J¼
5.9 Hz, H2), 2.61 (1H, br s, H1), 2.78–2.79 (1H, m, H4), 2.85 (1H,
dd, J ¼ 6.0, 4.5 Hz, H3), 3.30–3.61 (10H, m, 4  CH2, H5, H6),
4.47–4.57 (4H, m, 2  CH2Ar), 6.59 (1H, t, J ¼ 5.6 Hz, NH), 7.15–
7.18 (2H, m, ArH), 7.22–7.24 (2H, m, ArH), 7.37–7.39 (2H, m,
ArH), 7.44–7.47 (2H, m, ArH), 8.11 (1H, t, J ¼ 4.0 Hz, NH), 8.47
(1H, t, J ¼ 5.5 Hz, NH), 8.71 (1H, t, J ¼ 6.1 Hz, NH), 11.47 (1H, s,
NH), 11.53 (1H, s, NH). 13C NMR (125 MHz, CDCl3) d 28.1, 28.2,
28.4, 34.3, 39.4, 40.3, 40.4, 42.5, 43.6, 44.8, 45.2, 49.4, 71.5, 71.7,
78.7, 79.6, 80.2, 82.1, 83.4, 83.9, 122.5, 122.6, 126.2, 126.3, 130.0,
130.1, 130.66, 130.68, 130.72, 130.75, 141.0, 141.1, 153.2 (2  C),
156.9, 158.1, 163.1, 163.6, 172.2, 174.4. HRMS (ESI, m/z) for
C49H70Br2N8O12 [M + H]
+ calc. 1121.3553; found 1121.3541.General procedure E for Boc-removal of Boc-protected
guanidines 15a–i
To the stirring solution of Boc-protected guanidine (0.05 mmol)
and MeOH (520 mL), was added dropwise AcCl (20 equiv.) and
the reaction was stirred for 24 h at ambient temperature. The
reaction mixture was concentrated under vacuum and the
product was co-evaporated with MeOH (2  0.5 mL) to give the
desired guanidinium HCl salt.
5,6-Bis(methoxy)bicyclo[2.2.1]heptane-3-endo-2-exo-dicar-
boxamidoethylguanidine hydrogen chloride (16a). Compound
16a was prepared from Boc-protected diguanidine 15a (42 mg,
0.05 mmol) according to general procedure E as a white solid
(24 mg, 96%); m.p: 161.5–195.0 C (slow decomposition). 1H
NMR (270 MHz, CD3OD) d 1.50 (1H, d, J ¼ 10.8 Hz, H7a), 1.80
(1H, d, J ¼ 11.0 Hz, H7s), 2.46 (1H, br s, H2), 2.58–2.59 (1H, m,
H1), 2.65 (1H, d, J¼ 5.3 Hz, H4), 3.17 (1H, app. t, J¼ 4.5 Hz, H3),
3.33 (3H, s, OMe), 3.41 (3H, s, OMe), 3.35–3.43 (9H, m, 4  CH2,
H5), 3.51 (1H, d, J¼ 6.3 Hz, H6), 8.22 (1H, t, J¼ 4.5 Hz, NH), 8.32
(1H, t, J ¼ 4.6, NH). 13C NMR (67.5 MHz, CD3OD) d 33.9, 39.5,
39.7, 42.0, 42.2, 45.4, 46.1, 47.6, 47.8, 58.8, 58.9, 81.8, 85.4,
158.9, 175.0, 176.7. HRMS (ESI, m/z) for C17H32N8O4 [M + 2H]
2+
calc. 207.1346; found 207.1341.
5,6-Bis(benzyloxy)bicyclo[2.2.1]heptane-3-endo-2-exo-dicar-
boxamidoethylguanidine hydrogen chloride (16). Compound
16b was prepared from Boc-protected diguanidine 15b (76 mg,
0.08 mmol) according to general procedure E as a white residue
(47 mg, 96%). 1H NMR (500 MHz, CD3OD) d 1.56 (1H, d, J¼ 10.0
Hz, H7a), 2.02 (1H, d, J¼ 10.0 Hz, H7s), 2.53 (1H, br s, H2), 2.66–
2.67 (2H, m, H1, H4), 3.18 (1H, app. t, J ¼ 5.7 Hz, H3), 3.21–3.39
(8H, m, 4 CH2), 3.62 (1H, d, J¼ 5.3 Hz, H5), 3.73 (1H, d, J¼ 5.5
Hz, H6), 4.50–4.65 (4H, m, 2 ArCH2), 7.26–7.39 (10H, m, ArH).
13C NMR (125 MHz, CD3OD) d 34.3, 39.6, 39.7, 41.97, 42.01, 46.4
(2  C), 47.8, 48.4, 73.4, 73.7, 78.9, 83.2, 128.70, 128.72, 129.2 (2
 C), 129.32 (3  C), 129.33 (3  C), 139.6, 139.7, 158.8, 158.9,This journal is © The Royal Society of Chemistry 2015175.0, 176.7. HRMS (ESI, m/z) for C29H40N8O4 [M + 2H]
2+ calc.
283.1659; found 283.1667.
5,6-Bis[(2-methylbenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-
exo-dicarboxamidoethylguanidine hydrogen chloride (16c).
Compound 16c was prepared from Boc-protected diguanidine
15c (54 mg, 0.05 mmol) according to general procedure E as a
clear oil (8 mg, 24%). 1H NMR (500 MHz, CD3OD) d 1.56 (1H, d, J
¼ 10.3 Hz, H7a), 2.01 (1H, d, J¼ 9.5 Hz, H7s), 2.26 (3H, s, ArMe),
2.30 (3H, s, ArMe), 2.53 (1H, br s, H2), 2.63–2.69 (2H, m, H1,
H4), 3.14–3.38 (9H, m, 4 CH2, H3), 3.64 (1H, d, J¼ 5.1 Hz, H5),
3.76 (1H, d, J ¼ 5.5 Hz, H6), 4.49–4.67 (4H, m, 2  ArCH2), 7.08–
7.20 (7H, m, ArH), 7.29 (1H, d, J ¼ 7.3 Hz, ArH). 13C NMR (125
MHz, CD3OD) d 19.07, 19.09, 34.4, 39.6, 39.7, 41.98, 42.04, 46.2,
46.3, 47.8, 48.4, 72.0, 72.1, 79.2, 83.6, 126.68, 126.73, 128.96,
128.99, 130.2, 130.3, 131.1, 131.2, 137.4, 137.6, 138.1, 138.2,
158.86, 158.89, 175.1, 176.8. HRMS (ESI, m/z) for C31H44N8O4
calc. [M + 2H]2+ 297.1816; found 297.1820.
5,6-Bis[(4-triuoromethylbenzyl)oxy] bicyclo[2.2.1]heptane-
3-endo-2-exo-dicarboxamidoethylguanidine hydrogen chloride
(16d). Compound 16d was prepared from Boc-protected
diguanidine 15d (87 mg, 0.08 mmol) according to general
procedure E as a colourless sticky residue (40 mg, 66%). 1H
NMR (500 MHz, CD3OD) d 1.60 (1H, d, J ¼ 10.2 Hz, H7s), 2.06
(1H, d, J ¼ 9.9 Hz, H7a), 2.59 (1H, br s, H2), 2.70–2.72 (2H, m,
H1, H4), 3.21–3.38 (9H, m, 4 CH2, H3), 3.69 (1H, d, J¼ 5.2 Hz,
H5), 3.80 (1H, d, J ¼ 5.5 Hz, H6), 4.63 (2H, s, ArCH2), 4.69–4.76
(2H, m, ArCH2), 7.46–7.48 (2H, m, ArH), 7.51–7.52 (2H, m, ArH),
7.55–7.58 (4H, m, ArH). 13C NMR (125 MHz, CD3OD) d 34.3,
39.6, 39.7, 41.9, 42.0, 46.1, 46.2, 47.8, 48.4, 72.6, 72.7, 79.6, 83.6,
125.69 (q, 1JCF ¼ 269.7 Hz), 125.71 (q, 1JCF ¼ 269.7 Hz), 126.1 (q,
3JCF ¼ 3.4 Hz, 4  CH), 129.2 (4  C), 130.58 (q, 2JCF ¼ 31.8 Hz),
130.60 (q, 2JCF ¼ 31.7 Hz), 144.46, 144.54, 158.83, 158.85, 174.9,
176.6. 19F NMR (470 MHz, CD3OD) d 65.41, 65.38. HRMS
(ESI, m/z) for C31H38F6N8O4 [M + 2H]
2+ calc. 351.1533; found
351.1532.
5,6-Bis[(3-uorobenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-
exo-dicarboxamidoethylguanidine hydrogen chloride (16e).
Compound 16e was prepared from Boc-protected diguanidine
15e (72 mg, 0.07 mmol) according to general procedure E as a
yellow solid (46 mg, 99%); m.p: 77.4–82.4 C (slow decomposi-
tion). 1H NMR (500 MHz, CD3OD) d 1.58 (1H, d, J ¼ 10.2 Hz,
H7s), 2.02 (1H, d, J ¼ 10.0 Hz, H7a), 2.57 (1H, br s, H2), 2.68–
2.69 (2H, m, H1, H4), 3.19–3.38 (9H, m, 4  CH2, H3), 3.65 (1H,
d, J¼ 5.2 Hz, H5), 3.76 (1H, d, J¼ 5.6 Hz, H6), 4.53–4.58 (2H, m,
ArCH2), 4.62–4.68 (2H, m, ArCH2), 6.97–7.00 (2H, m, ArH), 7.05
(1H, d, J ¼ 9.8 Hz, ArH), 7.10–7.11 (2H, m, ArH), 7.16 (1H, d, J ¼
7.6 Hz, ArH), 7.28–7.34 (2H, m, ArH). 13C NMR (125 MHz,
CD3OD) d 34.3, 39.6, 39.7, 41.9, 42.0, 46.1 (2  C), 47.8, 48.3,
72.6, 72.7, 79.2, 83.4, 115.33 (d, 2JCF¼ 33.7 Hz), 115.26 (d, 2JCF¼
26.6 Hz), 115.40 (d, 2JCF ¼ 34.0 Hz), 115.43 (d, 2JCF ¼ 27.0 Hz),
124.50 (d, 4JCF¼ 2.7 Hz), 124.52 (d, 4JCF¼ 2.6 Hz), 131.02 (d, 3JCF
¼ 7.8 Hz), 131.08 (d, 3JCF ¼ 6.6 Hz), 142.6 (d, 3JCF ¼ 7.2 Hz),
142.8 (d, 3JCF ¼ 7.1 Hz), 158.79, 158.81, 164.22 (d, 1JCF ¼ 244.2
Hz), 164.23 (d, 1JCF ¼ 242.8 Hz), 174.9, 176.6. 19F NMR (470
MHz, CDCl3) d 116.03, 115.86. HRMS (ESI, m/z) for
C29H38F2N8O4 [M + 2H]
2+ calc. 301.1565; found 301.1576.RSC Adv., 2015, 5, 28582–28596 | 28593
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View Article Online5,6-Bis[(4-uorobenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-
exo-dicarboxamidoethylguanidine hydrogen chloride (16f).
Compound (16f) was prepared from Boc-protected diguanidine
15f (90 mg, 0.09 mmol) according to general procedure E as a
white solid (46 mg, 77%); m.p: 94.0–110.0 C (slow decompo-
sition). 1H NMR (500 MHz, CD3OD) d 1.55 (1H, d, J ¼ 10.1 Hz,
H7a), 2.01 (1H, d, J ¼ 9.0 Hz, H7s), 2.51 (1H, br s, H2), 2.62 (1H,
m, H1), 2.67 (1H, d, J ¼ 5.3 Hz, H4), 3.18–3.41 (9H, m, 4  CH2,
H3), 3.63 (1H, d, J ¼ 5.8 Hz, H5), 3.73 (1H, d, J ¼ 5.5 Hz, H6),
4.47–4.53 (2H, m, ArCH2), 4.59 (2H, s, ArCH2), 7.00–7.05 (4H, m,
ArH), 7.29–7.31 (2H, m, ArH), 7.34–7.37 (2H, m, ArH). 13C NMR
(125 MHz, CD3OD) d 34.3, 39.6, 39.7, 41.98, 42.04, 46.16, 46.20,
47.7, 48.6, 72.7, 72.9, 79.0, 83.2, 115.96 (d, 2JCF ¼ 21.0 Hz),
115.97 (d, 2JCF ¼ 21.6 Hz), 131.1 (d, 3JCF ¼ 8.1 Hz, 4  CH),
135.76 (d, 2JCF ¼ 15.4 Hz), 135.78 (d, 2JCF ¼ 15.6 Hz), 163.79 (d,
1JCF ¼ 243.2 Hz), 163.81 (d, 1JCF ¼ 242.9 Hz), 158.9 (2  C),
175.0, 176.7. 19F NMR (470 MHz, CDCl3) d 118.04, 117.89.
HRMS (ESI, m/z) for C29H38F2N8O4 [M + 2H]
2+ calc. 301.1565;
found 301.1567.
5,6-Bis[(3-bromobenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-
exo-dicarboxamidoethylguanidine hydrogen chloride (16g).
Compound 16g was prepared from Boc-protected diguanidine
15g (169 mg, 0.15 mmol) according to general procedure E as a
white solid (115 mg, 97%); m.p: 99.9–132.8 C (slow decompo-
sition). 1H NMR (500 MHz, CD3OD) d 1.57 (1H, d, J ¼ 10.5 Hz,
H7a), 2.01–2.04 (1H, m, H7s), 2.55 (1H, br s, H2), 2.66–2.69 (2H,
m, H1, H4), 3.19–3.40 (9H, m, 4  CH2, H3), 3.64 (1H, d, J ¼ 5.6
Hz, H5), 3.75 (1H, d, J ¼ 5.3 Hz, H6), 4.50–4.56 (2H, m, ArCH2),
4.59–4.65 (2H, m, ArCH2), 7.21–7.27 (3H, m, ArH), 7.32 (1H, d, J
¼ 7.7 Hz, ArH), 7.40–7.43 (3H, m, ArH), 7.48 (1H, m, ArH), 7.53
(1H, m, ArH). 13C NMR (125 MHz, CD3OD) d 34.3, 39.6, 39.7,
41.96, 42.0, 46.13, 46.15, 47.7, 48.4, 72.6, 72.7, 79.3, 83.5, 123.32,
123.35, 127.59, 127.62, 131.16, 131.21, 131.66, 131.70, 131.8 (2
 C), 142.4, 142.5, 158.86, 158.87, 175.0, 176.7. HRMS (ESI,m/z)
for C29H38Br2N8O4 [M + 2H]
2+ calc. 361.0764; found 361.0774.
5,6-Bis[(4-bromobenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-
exo-dicarboxamidoethylguanidine hydrogen chloride (16h).
Compound 16h was prepared from Boc-protected diguanidine
15h (57 mg, 0.05 mmol) according to general procedure E as a
clear oil (40 mg, 99%). 1H NMR (500 MHz, CD3OD) d 1.56 (1H, d,
J ¼ 10.2 Hz, H7s), 2.00 (1H, d, J ¼ 9.9 Hz, H7a), 2.53 (1H, br s,
H2), 2.64–2.67 (2H, m, H1, H4), 3.17–3.40 (9H, m, 4  CH2, H3),
3.61 (1H, d, J ¼ 5.6 Hz, H5), 3.73 (1H, d, J ¼ 5.6 Hz, H6), 4.46–
4.52 (2H, m, ArCH2), 4.56–4.62 (2H, m, ArCH2), 7.20–7.22 (2H,
m, ArH), 7.26–7.28 (2H, m, ArH), 7.43–7.46 (4H, m, ArH). 13C
NMR (125 MHz, CD3OD) d 34.3, 39.6, 39.7, 41.9, 42.0, 46.1, 46.2,
47.7, 48.4, 72.6, 72.8, 79.1, 83.3, 122.36, 122.40, 131.0 (4  C),
132.40 (2  C), 132.41 (2  C), 139.0, 139.1, 158.81, 158.84,
174.9, 176.6. HRMS (ESI, m/z) for C29H38Br2N8O4 [M + 2H]
2+
calc. 361.0764; found 361.0769.
5,6-Bis(allyloxy) bicyclo[2.2.1]heptane-3-endo-2-exo-dicar-
boxamidoethylguanidine hydrogen chloride (16i). Compound
16i was prepared from Boc-protected diguanidine 15i (126 mg,
0.15 mmol) according to general procedure E as a yellow solid
(24 mg, 31%); m.p: 79.9–85.9 C. 1H NMR (500 MHz, CD3OD) d
1.52 (1H, d, J ¼ 10.3 Hz, H7a), 1.92 (1H, d, J ¼ 9.3 Hz, H7s), 2.4428594 | RSC Adv., 2015, 5, 28582–28596(1H, br s, H2), 2.59 (1H, d, J ¼ 3.5 Hz, H1), 2.66 (1H, d, J ¼ 5.2
Hz, H4), 3.16 (1H, app. t, J ¼ 5.1 Hz, H3), 3.30–3.46 (8H, m, 4 
CH2), 3.57 (1H, d, J ¼ 6.0 Hz, H5), 3.63 (1H, d, J ¼ 5.4 Hz, H6),
4.00–4.09 (4H, m, 2  CH2O), 5.13–5.32 (4H, m, 2  CH2CH),
5.86–5.98 (2H, m, 2  CH2CH), 7.45–7.48 (2H, m, 2  NH). 13C
NMR (125 MHz, CD3OD) d 34.2, 39.6, 39.7, 42.0, 42.2, 46.1, 46.2,
47.9, 48.4, 72.7, 72.8, 79.4, 83.3, 117.1, 117.2, 136.2 (2  C),
158.87, 158.92, 175.0, 176.7. HRMS (ESI,m/z) for C21H36N8O4 [M
+ 2H]2+ calc. 233.1503; found 233.1502.Crystallography
Intensity data were collected with an CCD diﬀractometer using
Cu-Ka radiation, the temperature during data collection was
maintained at 130.0(1) using an Oxford Cryosystems cooling
device. The structure was solved by direct methods and diﬀer-
ence Fourier synthesis.53 Thermal ellipsoid plots were generated
using the program ORTEP-3 (ref. 54) integrated within the
WINGX55 suite of programs. Disordered solvent, assumed to be
ethanol was removed using the Squeeze procedure.56Disk diﬀusion – zone of inhibition assay
A stock solution of 10 mg mL1 was made for each compound
under observation using DMSO as a solvent. Each of these stock
solutions was then diluted by a factor of 1 : 2 to bring the
concentration to 5 mg mL1. The diluted solutions were then
lter-sterilized using a 0.2 mm Nylon lter, and 10 mL of the
5 mg mL1 stock was pipetted onto a blank disk (i.e. 50 mg per
disk; Oxoid Limited, Hampshire, UK). All bacterial isolates were
matched to a 0.5McFarland standard (in 0.9%NaCl) before they
were swabbed onto nutrient agar. The controls used were a
10 mg colistin disk (Oxoid), 10 mL of DMSO and a plate swabbed
with saline from the dispenser used.Minimum inhibitory concentration (MIC) determination
Bacteria were obtained from American Type Culture Collection
(ATCC; Manassas, VA, USA) as listed in Table S2 (see ESI†).
Bacteria were cultured in Nutrient broth (NB; Bacto Laborato-
ries, catalog no. 234000) or Muller-Hinton broth (MHB; Bacto
Laboratories, catalog no. 211443) at 37 C overnight with
shaking (180 RPM). A sample of each culture was diluted 50-
fold in fresh MHB and incubated at 37 C for 1.5–3 h with
shaking (180 RPM). Compound stock solutions were prepared
as 10 mg mL1 in DMSO and colistin was dissolved in Milli-Q
water at 5.12 mg mL1. The compounds, at twice the nal
desired concentration, were serially diluted 2-fold across the
wells of 96-well plates (Non-Binding Surface, Corning, catalog
no. 3641). Mid-log phase bacterial cultures (aer 1.5–3 h incu-
bation) were diluted to a nal concentration of 5  105 colony
forming units (CFU) per mL, and 50 mL was added to each well
giving a nal compound concentration range of 32 mg mL1 to
0.015 mg mL1 (DMSO # 1%). MICs were determined visually
aer 20 h of incubation at 37 C, with the MIC dened as the
lowest compound concentration at which no bacterial growth
was visible.This journal is © The Royal Society of Chemistry 2015
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View Article OnlineCytotoxicity evaluation
HEK293 (ATCC CRL-1573) and HepG2 (ATCC HB-8065) cells
were seeded as 3000 cells per well in a 384-well plate in DMEM
medium (GIBCO-Invitrogen #11995-073), in which 10% of FBS
was added. Cells were incubated for 24 h at 37 C, 5% CO2 to
allow cells to attach to the plates. A concentration series of
compounds was then added into each well. The cells were
incubated with the compounds for 24 h at 37 C, 5% CO2. Aer
the incubation, 10 mM resazurin (dissolved in PBS) was added to
each well. The plates were then incubated for 2 h at 37 C, 5%
CO2. The uorescence intensity was read using Polarstar Omega
with excitation/emission 560/590. The data was analysed by
Prism soware. Results are presented as the average percentage
of control  SD for each set of duplicate wells using the
following equation:
Percentage viability ¼ (FITEST  FINegative/FIUNTREATED
 FINegative)  100.Acknowledgements
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